A Promising Alzheimer’s Drug Faces Challenges in U.S. Market
A groundbreaking drug, Leqembi, touted as the first treatment to slow the progression of Alzheimer’s disease, made its debut in the U.S. market over a year ago. However, despite initial excitement, sales have fallen short of expectations.
Major hospital systems have been slow to adopt the drug, and some insurers have refused coverage, leaving patients struggling to access the potentially life-changing treatment. In addition, doctors warn of potential side effects, such as brain swelling and bleeding, which may deter patients from seeking the medication.
Although studies have shown that Leqembi can delay the progression of Alzheimer’s for a few months in patients with mild symptoms, the drug has faced hurdles in gaining widespread acceptance. It has received full approval from the FDA for those in the early stages of the disease, but challenges remain in terms of administering the drug and obtaining insurance coverage for necessary treatments.
Hospitals and health systems have needed more time to establish protocols for delivering Leqembi, and patients have encountered delays in receiving treatment due to insurance denials and eligibility issues. Doctors stress the importance of identifying patients quickly and initiating treatment before the disease advances.
While future treatments targeting the amyloid protein associated with Alzheimer’s are on the horizon, researchers believe that combination therapies may be necessary to effectively combat the disease. In the meantime, efforts are ongoing to address the barriers hindering access to Leqembi and improve outcomes for Alzheimer’s patients.
